MSD

News

Can Keytruda finally break into early head and neck cancer?

The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.

News

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.

News

With Merck circling, SpringWorks gets new drug approval

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

News

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.

News

MSD buys Irish vaccines plant from WuXi for €500m

MSD has expanded its presence in Ireland with an agreement to buy a vaccines manufacturing facility from WuXi Biologics in Dundalk.

News

MSD makes its obesity move with $2bn Hansoh deal

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.

Can Keytruda finally break into early head and neck cancer?

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

With Merck circling, SpringWorks gets new drug approval

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

MSD buys Irish vaccines plant from WuXi for €500m

MSD makes its obesity move with $2bn Hansoh deal

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks